Biography

Bruno Sarmento graduated in Pharmaceutical Sciences and is PhD in Pharmaceutical Nanotechnology at Univ Porto, in collaboration with Queen’s Univ, Univ Copenhagen and Univ Santiago de Compostela. He was post-doc fellow at Univ Porto in collaboration with Univ Copenhagen. In 2012 he became Associated Researcher at INEB, now part of i3S, Assistant Researched in 2016 and Principal Investigator in 2019, where he leads the Nanomedicines & Translational Drug Delivery group. He is currently invited Associate Professor at IUCS. He was Visiting Professor at UniOeste (BR) between 2015-2017 and at Shanghai Jiao Tong University (CH) between 2022-2024.

His research interests cover cutting-edge drug delivery systems, with a keen focus on nanomedicine. He has made significant and multidisciplinary contributions on engineering nanomedicines, multistage macroplatforms and 3D multicompartmental cell-based models, closely resembling the basic characteristics of healthy and injured tissues, as reliable pre-clinical platforms for drug and nanomedicines efficacy screening.

He has nurtured scientists and innovators by education and training, supervising 20 Post-Docs, 55 PhD and 40 MSc students and 20 researcher assistants. His group holds vary scientific backgrounds, diversity by gender (20% male/80% female), including researchers from more than 15 countries.

He hosted more than 25 mobility/foreigner PhD students, fostering a vibrant exchange of ideas and expertise and resulting in multiple publications in collaboration with international co-authors.

His research garnered international recognition, evident in his publication record of over 500 papers (>23000 citations, H-index 76), and more than 60 invited talks in international meetings in 20 countries. He attracted competitive funding from national (FCT, CCDR-N, CESPU) and international (EC, NIH, CAPES, FAPESP, Crohn’s & Colitis Foundation) grants, and partnership with pharmaceutical industries.

He serves the i3S Board of Directors since 2020, Director-at-Large and Secretary of the Controlled Release Society (CRS) and member of CRS College of Fellows. He is editor of Eur J Pharm Sci and Drug Deliv Transl Res, and Advisory Board of others as J Control Rel and Exp Opin Drug Deliv. He is a regular reviewer for high rank journals (Nat Nanotechnol, Sci Adv, Nat Com, Adv Mat, J Control Rel) and funding agencies (FNRS (BE), FWO(BE), CNCS (RO), FCT (PT), NSC (PL), ANR (FR), CNPq (BR), ERC, MC Actions, PathFinder, FetOpen (EC)).